Fruquintinib Maintenance Therapy After Adjuvant Chemotherapy in Advanced CRC: A Study on 2-Year Recurrence and Metastasis Rates
Explore the clinical effectiveness and safety of fruquintinib as maintenance therapy in advanced CRC patients achieving NED after completing adjuvant chemotherapy, with a focus on the 2-year recurrence and metastasis rate as the primary outcome measure.
原文地址: https://www.cveoy.top/t/topic/fww4 著作权归作者所有。请勿转载和采集!